Apelin for the treatment of type 2 diabetes

Use of Apelin in humans has a positive effect on insulin sensitivity with a good tolerance and a good safety. Thus, a first object of the invention relates to an APJ receptor agonist for use in the treatment or the prevention of diabetes.(Eur J Pharmacol. 2015 Sep 15;763(Pt B):149-59. doi: 10.1016/j.ejphar.2015.05.017. Review.)

Keywords: Apelin, APJ receptor
Patent Application number: EP15305422.6
Inventors:
Isabelle CASTAN-LAURELLLaurent CAZALSPhilippe VALETPierre GOURDY
Publications:
Eur J Pharmacol. 2015 Sep 15;763(Pt B):149-59. doi: 10.1016/j.ejphar.2015.05.017. Review.

You might also be interested in

Contact

Inserm Transfert

Research tool licensing team

researchtools@inserm-transfert.fr